RPG Life Sciences Limited AI Stock Analysis
Want to see IN:RPGLIFE full AI Analyst Report?
RPG Life Sciences Limited (RPGLIFE) AI Stock Analysis
RPG Life Sciences Limited
(NSE:RPGLIFE)
The score is primarily supported by strong financial flexibility from a conservative balance sheet, but it is meaningfully constrained by recent profitability and cash-flow deterioration. Technically, the stock is below key short-to-medium moving averages, and valuation is relatively expensive (high P/E with a modest yield), limiting upside without improved execution.
RPG Life Sciences Limited (RPGLIFE) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 42.20B
- Dividend Yield
- 0.94%
- Average Volume (3M)
- 1,376
- Price to Earnings (P/E)
- 38.0
- Beta (1Y)
- 0.80
- Revenue Growth
- 14.68%
- EPS Growth
- -49.22%
- Country
- India
- Employees
- 1,366
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
RPG Life Sciences Limited Business Overview & Revenue Model
Company Description
RPG Life Sciences Limited operates as a fully integrated pharmaceutical enterprise, engaged in the development, production, and commercialization of branded drug formulations, generic medications, and synthetic active pharmaceutical ingredients (APIs...
RPG Life Sciences Limited Financial Statement Overview
Summary
Strong balance sheet strength (very low leverage and solid ROE history) supports a high-quality profile, but the score is held back by recent margin compression and a notable deterioration in cash-flow conversion, with FY2026 free cash flow turning slightly negative.
Income Statement
78PositiveBalance Sheet
92Very PositiveCash Flow
58Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.64B | 7.08B | 6.53B | 5.77B | 5.09B | 4.37B |
| Gross Profit | 3.72B | 2.92B | 4.39B | 3.93B | 1.70B | 2.87B |
| EBITDA | 1.74B | 1.77B | 1.60B | 1.36B | 1.08B | 902.40M |
| Net Income | 1.09B | 1.15B | 1.83B | 876.60M | 676.40M | 514.80M |
Balance Sheet | ||||||
| Total Assets | 11.16B | 7.93B | 6.58B | 5.13B | 4.19B | 3.45B |
| Cash, Cash Equivalents and Short-Term Investments | 2.93B | 2.75B | 2.66B | 1.26B | 1.15B | 698.00M |
| Total Debt | 264.40M | 200.00M | 0 | 0 | 100.00K | 9.40M |
| Total Liabilities | 2.50B | 1.88B | 1.27B | 1.38B | 1.12B | 888.40M |
| Stockholders Equity | 6.87B | 6.05B | 5.31B | 3.75B | 3.08B | 2.56B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -800.00K | 418.30M | 251.30M | 580.90M | 408.00M |
| Operating Cash Flow | 0 | 652.80M | 778.60M | 943.60M | 908.20M | 647.50M |
| Investing Cash Flow | 0 | 761.70M | -418.00M | -791.50M | -1.06B | -346.60M |
| Financing Cash Flow | 0 | -196.90M | -270.80M | -203.10M | -171.20M | -135.10M |
RPG Life Sciences Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:RPGLIFE, the sentiment is Negative. The current price of 2551.45 is below the 20-day moving average (MA) of 2694.37, below the 50-day MA of 2770.05, and above the 200-day MA of 2374.59, indicating a neutral trend. The MACD of -67.18 indicates Positive momentum. The RSI at 41.98 is Neutral, neither overbought nor oversold. The STOCH value of 30.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:RPGLIFE.
RPG Life Sciences Limited Peers Comparison
Overall Rating
IN:IOLCP72Outperform
IN:BLISSGVS65Neutral
IN:RPGLIFE62Neutral
IN:HIKAL61Neutral
IN:UNICHEMLAB51Neutral
IN:SOLARA50Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 72Outperform | INR 59.18B | 29.14 | ― | 0.50% | 26.76% | 75.41% | |
| 65Neutral | INR 71.56B | 44.52 | ― | 0.22% | 24.87% | 46.37% | |
| 62Neutral | INR 42.20B | 38.01 | ― | 0.94% | 14.68% | -49.22% | |
| 61Neutral | INR 27.45B | -556.17 | ― | 0.27% | 8.93% | -149.51% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 51Neutral | INR 35.07B | 10.36 | ― | ― | 6.44% | 283.10% | |
| 50Neutral | INR 33.20B | 89.33 | ― | ― | 27.30% | 456.80% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:RPGLIFE | RPG Life Sciences Limited | 2551.45 | 260.83 | 11.39% | |
| IN:BLISSGVS | Bliss Gvs Pharma Limited | 673.00 | 510.22 | 313.45% | |
| IN:HIKAL | Hikal Limited | 222.60 | -10.59 | -4.54% | |
| IN:IOLCP | IOL Chemicals & Pharmaceuticals Ltd. | 201.60 | 107.48 | 114.19% | |
| IN:SOLARA | Solara Active Pharma Sciences Ltd. | 690.60 | 115.45 | 20.07% | |
| IN:UNICHEMLAB | Unichem Laboratories Limited | 498.05 | 21.60 | 4.53% |
RPG Life Sciences Limited Corporate Events
RPG Life Sciences Files Investor Presentation on FY27 Q2 and H1 Results
RPG Life Sciences Limited has submitted an investor presentation to Indian stock exchanges detailing its unaudited financial results for the quarter and half year ended September 30, 2026. The disclosure underscores the company’s ongoing efforts to m...
RPG Life Sciences Subsidiary RPG Active Pharma to Merge Actis Generics
RPG Life Sciences has announced that the board of its subsidiary RPG Active Pharma Limited has approved a scheme of amalgamation to merge its wholly owned subsidiary Actis Generics Private Limited into RPG Active Pharma. The transaction is a related-...
RPG Life Sciences Completes Acquisition of Actis Generics
RPG Life Sciences Limited has completed the acquisition of Actis Generics Private Limited through its subsidiary RPG Active Pharma Limited, following a share purchase agreement signed on July 29, 2026. As of September 24, 2026, Actis Generics becomes...
RPG Life Sciences Completes Acquisition of API Business via Slump Sale
RPG Life Sciences has announced that its subsidiary RPG Active Pharma Limited has completed the business transfer agreement with Raghava Life Sciences Private Limited for the acquisition of active pharmaceutical ingredients and intermediates business...
RPG Life Sciences Posts Analyst Call Recording for Investor Access
RPG Life Sciences Limited has informed the stock exchanges that the recording and related details of its analyst and institutional investor call held on September 3, 2026 are now available on the company’s website for public access. The disclosure un...
RPG Life Sciences to Brief Investors on API Business in Scheduled Conference Call
RPG Life Sciences Limited has scheduled an analyst and institutional investor conference call to provide an update on its API business, with senior management, including the managing director and chief financial officer, set to address participants....
RPG Life Sciences Circulates Investor Presentation on Active Pharma Transaction
RPG Life Sciences Limited has notified India’s major stock exchanges that it has prepared an investor presentation for analysts and institutional investors. The company, which operates in the pharmaceutical sector and is listed on NSE and BSE, contin...
RPG Life Sciences Cancels Scheduled Investor and Analyst Meet
RPG Life Sciences Limited has announced that its previously scheduled investors and analysts meeting, which was to be held on Wednesday, September 2, 2026, at 10:00 a.m., has been cancelled. The company informed the stock exchanges in compliance with...
RPG Life Sciences injects Rs 65.69 crore into wholly owned pharma subsidiary
RPG Life Sciences Limited has invested up to Rs 65.69 crore in its wholly owned subsidiary, RPG Active Pharma Limited through a rights issue of equity shares. Following the allotment of 21,89,535 shares on August 14, 2026, RPG Life Sciences’ sharehol...
RPG Life Sciences Completes Transfer of API Business to Subsidiary
RPG Life Sciences Limited has completed the transfer of its active pharmaceutical ingredients business to RPG Active Pharma Limited, a wholly owned subsidiary, under a business transfer agreement executed on a slump sale basis. The transaction, effec...
RPG Life Sciences Moves API Chief to Lead Subsidiary RPG Active Pharma
RPG Life Sciences Limited has announced a key change in its senior management, centered on its API operations and subsidiary governance. The move reflects the company’s practice of aligning leadership roles with its multi-entity pharmaceutical struct...
RPG Life Sciences to Join Emkay Confluence 2026 Investor Meet
RPG Life Sciences Limited has informed the stock exchanges that it will participate in the Emkay Confluence 2026, an analyst and institutional investors meet scheduled in Mumbai on August 13, 2026, starting at 9:00 a.m. IST. The session will be a phy...
RPG Life Sciences Discloses Retirement of Senior Sales and Marketing Executive
RPG Life Sciences Limited has announced that Mr. Samir Rane, Vice President, Sales & Marketing – Main Division, has retired upon attaining the age of superannuation and consequently ceased to be part of the company’s senior management. The change, ef...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 31, 2026
